Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797140 | 0.90 | ALOX5 (0.37) | KDM4EALOX5ALDH1A1HPGDCYP1A2 | |
| SCHEMBL6798912 | 0.85 | KDM4E (0.37) | KDM4EALOX5ALDH1A1HPGDCYP1A2 | |
| SCHEMBL6798402 | 0.84 | KDM4E (0.37) | KDM4EALOX5ALDH1A1HPGDCYP1A2 | |
| SCHEMBL6792820 | 0.84 | LDHA (0.30) | LDHA | |
| SCHEMBL6798023 | 0.82 | ALDH1A1 (0.39) | KDM4EALOX5ALDH1A1HPGDCYP1A2 | |
| SCHEMBL6800234 | 0.82 | KDM4E (0.37) | KDM4EALOX5ALDH1A1HPGDCYP1A2 | |
| SCHEMBL6797332 | 0.82 | POLB (0.34) | KDM4EALOX5ALDH1A1HPGDCYP1A2 | |
| SCHEMBL6797139 | 0.82 | ALDH1A1 (0.40) | KDM4EALOX5ALDH1A1HPGDCYP1A2 | |
| SCHEMBL6798204 | 0.81 | KDM4E (0.35) | KDM4EALOX5ALDH1A1HPGDCYP1A2 | |
| SCHEMBL6797518 | 0.79 | KDM4E (0.40) | KDM4EALOX5ALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734205-B2 | SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20030018056-A1 | Substituted guanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1238971-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018056-A1 | Substituted guanidine derivatives | SLC28A1, SLC7A1, ABCB11 | KDM4E 1068/4885ALOX5 2297/4885ALDH1A1 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.